ClinicalTrials.gg
RecruitingNCT06020924Updated Oct 13, 2026

The Effects of Uterine Fibroids on Pregnancy in Women

An observational study in Female Infertility and Uterine Fibroid, sponsored by Wenwen Wang. Recruiting at 1 site in China. Open to female participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Wenwen Wang · Observational

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Oct 13, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
1,658
Ages
20 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Infertility, Female with a site in China — 17 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.

Started
2023
with 6 others
Observational
7 of 58
1 open now
Primary completion
2026-12
later than 14 of 19 live
Registered
37th of 58
by date

Among the 58 studies in Infertility, Female with a site in China, this one is one of 7 that started in 2023, is one of 7 observational ones, reaches primary completion later than 14 of the 19 other live ones, and was the 37th registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

17 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 20 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Infertility, Female with a site in China, or all of them as a file.
02

Study summary

Female fertility may be affected by uterine fibroids, although this association has not been elucidated. This retrospective cohort study aims to evaluate the impact of fibroids on women fertility.

Read the detailed description

Infertility is defined as the inability of a couple to achieve pregnancy over an average period of one year of unprotected sexual intercourse. Currently, one in six couples is affected by infertility worldwide. With the development of society bringing enormous material and spiritual wealth to human beings, comprehensive factors such as environmental pollution, life and work pressure and bad habits have an important impact on fertility. Infertility is a disease that seriously affects the physical and mental health of patients and brings about serious social problems. According to the World Health Organization (WHO), infertility will become the third major disease in the 21st century following tumor and cardiovascular diseases.

Infertility can be caused by a single factor or multiple factors together. The WHO proposed a classification method based on etiological diagnosis to classify infertility into six major causes: ovulation factors, fallopian tube problems, uterine factors, cervical factors, male factors and psychosocial factors. There is a serious impact on female fertility due to heredity, auto-immunity, infection, metabolic abnormalities, surgery and other factors. The main factors leading to female infertility include patient age, education level, weight (obesity), menstrual history (irregular menstrual cycle), pregnancy history (stillbirth and abortion history), disease history (ovarian cyst, ovarian aging, endocrine autoimmune diseases, fallopian tube abnormalities, pelvic abnormalities and uterine abnormalities), sexual history, previous surgical history, smoking history, chemical exposure history, and mental stress, etc. The objective of this study is to explore the impact of uterine fibroids on female pregnancy rate.

Uterine fibroid is a common benign tumor of female reproductive tract, with 25% to 50% of women of childbearing age suffering from uterine fibroid. The fibroids can cause various clinical symptoms, including menorrhagia, prolonged menstruation, pelvic compression and pain, as well as infertility and obstetric complications, but mostly are asymptomatic. The prevalence of fibroids increases with the age of women, while the fertility rate declines with ages. This complex relationship is particularly harmful. The mechanisms related to fibroids and infertility vary with the type and location of fibroids, including anatomical structure deformation, and interference with the physiological changes of endometrium and implantation of zygotes. In addition, fibroids can destroy the anatomical structure of the pelvis and disrupt the function of the fallopian tube. The FIGO classification describes nine types of fibroids: submucosal fibroids (type 0, Ⅰ, Ⅱ), intramural fibroids (types Ⅲ, Ⅳ, Ⅴ), and subserous fibroids (types Ⅵ and Ⅶ). Among them, submucosal and some intramural fibroids can lead to endometrial inflammatory environment, affecting sperm migration and embryo implantation.

Nevertheless, there is still controversy in epidemiological studies regarding the relationship between uterine fibroids and female infertility. Parity has a significant protective effect against fibroid development, and in fact infertile women may be at higher risk for fibroids. Similarly, it is difficult to distinguish whether fibroids have a direct deleterious effect on infertility, or whether the fibroid-infertility association is mediated by concomitant factors that affect fertility. In addition, the impact of each type of fibroids on fertility varies by the difference in the number, size, and location of fibroids, and the combinations of different fibroids may have special effects. Do uterine fibroids already exist when women plan and attempt to conceive? Do uterine fibroids have negative effects on fertility during this period? It is an urgent need to solve this problem at the present. Therefore, this study is of great significance for us to understand the impact of fibroids on female fertility and guide the treatment patterns of female patients with uterine fibroids who have fertility needs.

03

Conditions studied

  • Female Infertility
  • Uterine Fibroid

Keywords

  • Infertility
  • Uterine fibroids
  • Pregnancy rate
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Female patients with uterine fibroids

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 20-50 years
  2. Diagnosed with uterine fibroids (by ultrasound or pathology) combined with infertile or non-infertile patients
  3. Complete clinical data.

Exclusion criteria

Exclusion Criteria:

  1. Severe infectious disease or rheumatic immune disease active stage
  2. Previous history of malignant tumors
  3. Incomplete clinical data.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
1,658 participants (estimated)
Patient registry
No

Groups and cohorts

  • UFs with infertile patients

    Uterine fibroids combined with infertile women

    Other: No intervention

  • UFs with non-infertile patients

    Uterine fibroids combined with non-infertile women

    Other: No intervention

Interventions

  • OtherNo intervention

    This study is a retrospective observational study without intervention.

06

What researchers measure

Primary outcomes

  1. The pregnancy rate varies with different types and size of fibroids.

    Fibroid types range from 0 to 8 according to the FIGO classification. The pregnancy rate varies with different types and size of fibroids. Subserosal fibroids do not exert any detrimental effects on fertility outcomes. Submucosal fibroids have negatively impact fertility. The effect of intramural fibroids on reproductive outcome has been a subject of debate in the past, but recent literature indicates that intramural myomas also negative impact fertility.

    Time frame: through study completion, an average of 2.5 year

Secondary outcomes

  1. The rate of spontaneous abortion varies with different types and size of fibroids.

    Fibroids are a source of several obstetric complications, including spontaneous abortion, preterm birth, cesarean section, placental abruption, postpartum hemorrhage, and breech presentation. Submucosal fibroids and multiple myomas have an increased risk of miscarriage. The rate is calculated as the proportion of the number of miscarriage to the total number of pregnancies in different types of fibroids.

    Time frame: through study completion, an average of 2.5 year

  2. The rate of preterm birth varies with different types and size of fibroids.

    Fibroids measuring more than 5 centimetre (cm) have been linked to delivery at earlier gestational age. The ratio is calculated as the proportion of fibroids combined with preterm birth to fibroids combined with live birth.

    Time frame: through study completion, an average of 2.5 year

  3. The rate of cesarean section varies with different types and size of fibroids.

    Greater size and number of fibroids were associated with increased incidence of cesarean delivery. The ratio is calculated as the proportion of fibroids combined with cesarean section to total births.

    Time frame: through study completion, an average of 2.5 year

  4. The rate of placental abruption varies with different types and size of fibroids.

    Fibroids have an increased risk of placental abruption in patients. The ratio is calculated as the proportion of fibroids combined with placental abruption to total patients.

    Time frame: through study completion, an average of 2.5 year

  5. The rate of postpartum hemorrhage varies with different types and size of fibroids.

    There is an independent association of uterine leiomyomata with increased risk of severe postpartum hemorrhage. Submucosal fibroids are less implicated in bleeding events than intramural and subserosal ones. Great rates of hemorrhage are related with the biggest lesions. The ratio is calculated as the proportion of fibroids combined with postpartum hemorrhage to total patients.

    Time frame: through study completion, an average of 2.5 year

  6. The rate of malpresentation varies with different types and size of fibroids.

    Patients with fibroids have an increased risk of breech presentation. Malpresentation may be more related to multiple fibroids an to those bigger than 10 cm. The ratio is calculated as the proportion of fibroids combined with malpresentation to total patients.

    Time frame: through study completion, an average of 2.5 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Aug 2023 → Jun 2023, primary completion Nov 2025 → Dec 2026 and completion Nov 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2023
First posted
Sep 1, 2023
StartActual
Jun 1, 2023was Aug 2023
Primary completionEst.
Dec 31, 2026was Nov 2025
CompletionEst.
Dec 31, 2027was Nov 2025
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 31, 2023→Jun 1, 2023 (actual)
Oct 13, 2026
Primary completion
Nov 30, 2025→Dec 31, 2026
Oct 13, 2026
Study completion
Nov 30, 2025→Dec 31, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Aug 31, 2023→Jun 1, 2023 (now actual)
    Primary completion Nov 30, 2025→Dec 31, 2026
    Study completion Nov 30, 2025→Dec 31, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06020924
Lead sponsor
Wenwen Wang
Responsible party
Wenwen Wang (Professor, Tongji Hospital) — Sponsor-investigator
First posted
Sep 1, 2023
Start date
Jun 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Shixuan Wang
Contact
shixuanwang@tjh.tjmu.edu.cn
86-27-83663078
Shixuan Wang
principal investigator · Huazhong University of Science and Technology, Wuhan, Hubei, China, 430000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion